IBJNews

Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa

Back to TopCommentsE-mailPrintBookmark and Share

Canada’s Supreme Court dismissed Eli Lilly and Co.’s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.

The country’s highest court said in a statement Thursday that it decided not to look at the case after hearing from parties involved in the matter earlier this week. A Federal Court in 2011 ruled the patent was invalid because it did not meet “utility” requirements.

The Indianapolis-based firm has claimed recent decisions by Canadian courts invalidating 17 drug patents over “utility” requirements have made the country an outlier among major developed countries, prompting the company in December to notify Canada of its plans to file a trade complaint over its patent for its Strattera drug.

“Addressing Canada’s outlier status with respect to the interpretation of patent law is a priority for Lilly,” the company said in a statement Thursday. “We will continue to consider all our legal options to protect what we believe to be valid intellectual property rights protecting our patents in Canada.”

ADVERTISEMENT

  • Zyprexa off-patent profits
    Generic Zyprexa (Olanzapine) still a cash cow for Lilly. Well, Lilly did make an astounding $70 billion to date on Zyprexa and sales off-patent are still at $2 billion year.Not a bad hunk of change.-Daniel Haszard Zyprexa patient who got diabetes from it's side effect

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT